Trial reportJournal of clinical immunology1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humans.
Trial report in Journal of clinical immunology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 91 citations in OpenAlex.
- IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infection.Journal of translational medicine · 2025Article
- Pre-Clinical Assessment of Roflumilast Therapy in a Thoracic Model of Spinal Cord Injury.Pharmaceutics · 2023Article
- Oleic acid-related anti-inflammatory effects in force-stressed PdL fibroblasts are mediated by H3 lysine acetylation associated with alteredEpigenetics · 2022Article
- Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.Digestive diseases and sciences · 2022Review
- Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury.Journal of neuroinflammation · 2019Article
- Mathematical modeling of energy consumption in the acute inflammatory response.Journal of theoretical biology · 2019Article
- New treatment options for alcoholic hepatitis.World journal of gastroenterology · 2016Review
- Molecular targets in the treatment of alcoholic hepatitis.World journal of gastroenterology · 2012Review
- Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha on the endothelium of murine aorta.American journal of physiology. Heart and circulatory physiology · 2010Article
- Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.Digestive diseases and sciences · 2010Review
- Medroxyprogesterone acetate modulates remodeling, immune cell census, and nerve fibers in the cervix of a mouse model for inflammation-induced preterm birth.Reproductive sciences (Thousand Oaks, Calif.) · 2009Article
- Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions.American journal of physiology. Heart and circulatory physiology · 2008Article
- Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE.Annals of the rheumatic diseases · 2003Article
- Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice.Antimicrobial agents and chemotherapy · 1998Article
- Measurement of induced cytokines in AIDS clinical trials using whole blood: a preliminary report. ACTG Inducible Cytokines Focus Group. AIDS Clinical Trials Group.Clinical and diagnostic laboratory immunology · 1998Article
- IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways.The EMBO journal · 1998Article
- Recent advances in the treatment of malignant melanoma with gene therapy.Molecular medicine (Cambridge, Mass.) · 1997Review
- Article
- Effects of ceftriaxone on systemic and central expression of anti- and pro-inflammatory cytokines in alcohol-preferring (P) rats exposed to ethanol.Alcohol and alcoholism (Oxford, Oxfordshire)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
We conducted a double-blind, placebo-controlled study to investigate the safety, pharmacokinetics, and immunological properties of interleukin-10 (IL-10) administration in healthy humans. Volunteers received a single intravenous bolus injection of recombinant human IL-10 (1, 10, or 25 micrograms/kg) or placebo. Cytokine production in whole blood and peripheral blood mononuclear cells (PBMC) was assessed before and 3, 6, 24, and 48 hr after the injection. Peak serum concentrations of IL-10 (15 +/- 1.1, 208 +/- 20.1, and 505 +/- 22.3 ng/ml) occurred after 2-5 min for 1, 10, and 25 micrograms/kg IL-10, respectively. The terminal-phase half-life was 3.18 hr. A transient leukocytosis (24-63% above baseline) was observed 6 hr after injection, which coincided with a dose-dependent decrease (12-24%) in neutrophil superoxide generation. There was a marked inhibition (60-95%) of endotoxin-induced IL-6 production from whole blood in each group receiving IL-10. Production of IL-8 in endotoxin-stimulated blood was reduced in the 10 micrograms/kg group. In PBMC stimulated with phytohemagglutinin and phorbol ester, there was a decrease (72-87%) in interferon-gamma (IFN gamma) production 6 hr after IL-10 with a return to pre-IL-10 levels after 24 hr. This reduction was only partially associated with a decrease in the number of CD2-bearing cells. We conclude that IL-10 administration into humans is without significant side effects, and a single injection reduces ex vivo production of IL-6, IL-8, and IFN gamma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.